A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants
Status:
Recruiting
Trial end date:
2025-12-22
Target enrollment:
Participant gender:
Summary
The purpose of the study is to find out if the new drug sabatolimab when given in combination
with azacitidine and venetoclax, is safe and has beneficial effects in participants with high
or very high risk myelodysplastic syndrome (MDS) who are not suitable for treatment with
intensive chemotherapy or a stem-cell transplant (HSCT).